The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Trichomonas vaginalis Antimicrobial Drug Resistance in 6 US Cities, STD Surveillance Network, 2009–2010
Open accessAbstract
Nitroimidazoles (metronidazole and tinidazole) are the only recommended drugs for treating Trichomonas vaginalis infection, and previous samples that assessed resistance of such isolates have been limited in geographic scope.We assessed the prevalence of in vitro aerobic metronidazole and tinidazole resistance among T. vaginalis isolates from multiple geographic sites in the United States.Swab specimens were obtained from women who underwent routine pelvic examinations at sexually transmitted disease clinics in 6 US cities. Cultured T. vaginalis isolates were tested for nitroimidazole resistance (aerobic minimum lethal concentration [MLC] >50 μg/mL).Of 538 T. vaginalis isolates, 23 (4.3%) exhibited low-level in vitro metronidazole resistance (minimum lethal concentrations 50-100 μg/mL).No isolates exhibited moderate-to high-level metronidazole resistance or tinidazole resistance.Results highlight the possibility that reliance on a single class of antimicrobial drugs for treating T. vaginalis infections may heighten vulnerability to emergence of resistance.Thus, novel treatment options are needed.T richomoniasis, caused by Trichomonas vaginalis, is one of the most common nonviral sexually transmitted diseases (STDs): annually, ≈248 million incident cases occur worldwide, and ≈7.4 million cases occur in the United States (1,2).The estimated US prevalence of T. vaginalis infection is 3.1%, with a higher prevalence among black women and women of low socioeconomic status than among other women (3).Trichomoniasis is a frequent cause of vaginitis and can contribute to premature rupture of membranes during pregnancy, preterm birth, low birth weight, and may facilitate HIV acquisition (4-7).The Centers for Disease Control and Prevention (CDC) (Atlanta, Georgia, USA) STD Treatment Guidelines recommends the use of a 5-nitroimidazole antimicrobial agent, either metronidazole or tinidazole, for the treatment of T. vaginalis infection (8).Metronidazole has been the mainstay of treatment for several decades; however, tinidazole has better in vitro activity and is well tolerated (8).The reliance on a single drug class for treating T. vaginalis infections may be problematic if resistance to nitroimidazole becomes widespread in T. vaginalis strains.Three small studies that examined the prevalence of in vitro resistance in the United States have been conducted during the past 15 years, but they were limited in geographic scope (9-11).Our objective was to assess the prevalence of in vitro aerobic metronidazole and tinidazole resistance among a broad sample of T. vaginalis isolates from multiple geographic sites in the United States. MethodsDemographic data and T. vaginalis isolates were collected from women attending 6 STD clinics participating in the STD Surveillance Network (SSuN).SSuN is a sentinel site surveillance network which, through the implementation of common protocols for collecting, reporting, and analyzing enhanced surveillance data, aims to improve the capacity of national, state, and local STD programs to detect, monitor, and respond rapidly to trends in STDs.T. vaginalis specimens from women undergoing Trichomonas vaginalis Antimicrobial Drug Resistance in 6 US Cities, STD Surveillance Network, 2009-2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trichomonas vaginalis Associated With Low Birth Weight and Preterm Delivery
COTCH, M. F., PASTOREK, J. G., NUGENT, R. P., HILLIER, S. L., GIBBS, R. S., MARTIN, D. H., ESCHENBACH, D. A., EDELMAN, R., CAREY, C. J., REGAN, J. A., et al. (1997) · Sexually Transmitted Diseases · doi:10.1097/00007435-199707000-00008 · Cited by 836
Cited by
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Self-citationSexually transmitted diseases treatment guidelines (2015)
Workowski, K., & BOLAN, G. A. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.24.51-56 · Cited by 2,698
Self-citationSexually Transmitted Diseases Treatment Guidelines, 2010
(2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,076
Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines
Workowski, K. A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ771 · Cited by 588
Self-citationThe clinical spectrum of Trichomonas vaginalis infection and challenges to management
Muzny, C. A., & Schwebke, J. R. (2013) · Sexually Transmitted Infections · doi:10.1136/sextrans-2012-050893 · Cited by 53
Self-citation
Metadata
- Authors
- Kirkcaldy, R. D., Augostini, P., Asbel, L. E., Bernstein, K. T., Kerani, R. P., Mettenbrink, C. J., Pathela, P., Schwebke, J. R., Secor, W. E., Workowski, K. A., Davis, D., Braxton, J., & Weinstock, H. S.
- Venue
- Emerging Infectious Diseases
- Published
- 2012-06
- Volume
- 18
- Issue
- 6
- Pages
- 939-943
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- OpenAlex
- W2078495656
- Cited by
- 219
- References
- 1
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.